دورية أكاديمية
أعرض في EDS

Association between bronchiectasis exacerbations and longitudinal changes in FEV 1 in patients from the US bronchiectasis and NTM research registry.

التفاصيل البيبلوغرافية
العنوان: Association between bronchiectasis exacerbations and longitudinal changes in FEV 1 in patients from the US bronchiectasis and NTM research registry.
المؤلفون: Aksamit TR; Mayo Clinic, Rochester, MN, USA. Electronic address: Aksamit.Timothy@mayo.edu., Lapinel NC; Northwell Health, New Hyde Park, NY, USA; Louisiana State University Health Sciences Center, New Orleans, LA, USA., Choate R; University of Kentucky College of Public Health, Lexington, KY, USA., Feliciano J; Insmed Incorporated, Bridgewater, NJ, USA., Winthrop KL; Oregon Health and Science University, Portland, OR, USA., Schmid A; University of Kansas Medical Center, Kansas City, KS, USA., Wu J; Insmed Incorporated, Bridgewater, NJ, USA., Fucile S; Insmed Incorporated, Bridgewater, NJ, USA., Metersky ML; University of Connecticut School of Medicine, Farmington, CT, USA.
مؤلفون مشاركون: Bronchiectasis and NTM Research Registry Investigators
المصدر: Respiratory medicine [Respir Med] 2024 Jul; Vol. 228, pp. 107660. Date of Electronic Publication: 2024 May 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 8908438 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3064 (Electronic) Linking ISSN: 09546111 NLM ISO Abbreviation: Respir Med Subsets: MEDLINE
أسماء مطبوعة: Publication: 2003- : Oxford : Elsevier
Original Publication: London : Baillière Tindall, in association with the British Thoracic Society, [c1989-
مواضيع طبية MeSH: Bronchiectasis*/physiopathology , Disease Progression* , Registries*, Humans ; Male ; Female ; Forced Expiratory Volume/physiology ; Retrospective Studies ; Middle Aged ; Aged ; Longitudinal Studies ; Mycobacterium Infections, Nontuberculous/physiopathology ; Mycobacterium Infections, Nontuberculous/complications ; United States/epidemiology ; Adult ; Follow-Up Studies
مستخلص: Background: This study aimed to evaluate the association between the number of non-cystic fibrosis bronchiectasis (bronchiectasis) exacerbations during baseline and follow-up (objective 1) and to identify longitudinal changes in FEV 1 associated with exacerbation frequency (objective 2).
Methods: This was a retrospective cohort study of adult patients enrolled in the US Bronchiectasis and Nontuberculous Mycobacteria Research Registry September 2008 to March 2020. Objective 1 outcome was association between exacerbations during baseline (24 months) and 0-to-24 month and 24-to-48 month follow-up windows. Objective 2 outcomes were change in FEV 1 and FEV 1 % predicted over 24 months stratified by baseline exacerbation frequency.
Results: Objective 1 cohort (N = 520) baseline frequency of any exacerbations was 59.2%. Overall, 71.4% and 75.0% of patients with ≥1 baseline exacerbations had ≥1 exacerbations during the 0-to-24 and 24-to-48 month follow-ups. Having ≥1 exacerbation during baseline was significantly associated with ≥1 exacerbation during the 0-to-24 month (P = 0.0085) and 24-to-48 month follow-ups (P=<0.0001). Objective 2 cohort (N = 431) baseline FEV 1 was significantly lower in patients who had more exacerbations; however, decline in FEV 1 from baseline was not significantly different between patients with 0, 1, and ≥2 exacerbations. In patients with more baseline exacerbations, FEV 1 % predicted was significantly lower at baseline (P < 0.0001) and at 12 (P = 0.0002) and 24 month follow-ups (P < 0.0001).
Conclusions: Patients with frequent bronchiectasis exacerbations may be more likely than those with less frequent exacerbations to experience disease progression based on future exacerbation frequency and lower FEV 1 at baseline, although FEV 1 decline may not differ by baseline exacerbation frequency.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Joseph Feliciano, Jasmanda Wu, and Sebastian Fucile are employees and shareholders of Insmed Incorporated. Timothy R. Aksamit reports no personal grant or research support from Insmed Incorporated or other pharma; clinical trial design and participation with AstraZeneca, Insmed Incorporated, Johnson & Johnson, Redhill Biopharma, Spero Therapeutics, and Zambon, with all support going to the Mayo Foundation for Medical Education and Research; and is the medical director of Bronchiectasis and NTM 360 for the COPD Foundation. Nicole C. Lapinel reports receiving consulting fees and serving on the advisory board panel for Insmed Incorporated; Louisiana State University Health Sciences Center received clinical trial support from Insmed Incorporated. Radmila Choate and Andreas Schmid have nothing to disclose. Kevin L. Winthrop reports grant and research support and consulting fees from AN2 Therapeutics, Insmed Incorporated, Paratek, Red Hill Biopharma, Renovion, and Spero Therapeutics and participation on a data safety monitoring board or advisory board for Red Hill Biopharma. Mark L. Metersky reports receiving consulting fees from AN2 Therapeutics, Boehringer Ingelheim, Insmed Incorporated, Renovion, and Zambon.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
فهرسة مساهمة: Keywords: Bronchiectasis; Exacerbations; Patient registry; Real-world evidence
تواريخ الأحداث: Date Created: 20240511 Date Completed: 20240606 Latest Revision: 20240606
رمز التحديث: 20240607
DOI: 10.1016/j.rmed.2024.107660
PMID: 38734153
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا